A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90024, United States
Saint Charles, Missouri 63301, United States
North Charleston, South Carolina 29406, United States
Vancouver, British Columbia V6Z 2L4, Canada
Mississauga, Ontario L5M 4N4, Canada
Gdansk, 80-952, Poland
Bucharest, 041915', Romania